chufangao/CTO huggingface dataset:
Clinical trial NCT05174065: Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)
Official title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Apremilast (AMG 407) in Japanese Subjects With Palmoplantar Pustulosis (PPP)
Sponsor: Amgen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 176.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-03-08
Primary completion date: 2023-08-19
Completion date: 2024-06-01
Plan to share individual participant data: YES
IPD sharing description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
IPD time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
IPD access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Clinical trial NCT03559699: A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)
Official title: An Open-Label Study To Evaluate the Efficacy and Safety of AG-348 in Regularly Transfused Adult Subjects With Pyruvate Kinase (PK) Deficiency
Sponsor: Agios Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 27.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-06-26
Primary completion date: 2020-11-12
Completion date: 2020-11-12
Baseline population: Full analysis set included all participants who received at least 1 dose of study drug.
Plan to share individual participant data: NO
Clinical trial NCT04018599: Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS
Official title: A Phase I, Randomized, Open-label, Parallel-group Study to Determine the Pharmacokinetics, Safety, and Tolerability of MSB11022 (Proposed Adalimumab Biosimilar) Following a Single Subcutaneous Injection by an Auto-injector or by a Pre-filled Syringe in Healthy Subjects
Sponsor: Fresenius Kabi SwissBioSim GmbH (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 216.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-07-15
Primary completion date: 2020-03-17
Completion date: 2020-03-17
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04594070: Daily Versus Alternate Day Iron Supplementation for the Treatment of Iron Deficiency Anemia in Pregnancy
Official title: A Randomized Trial of Intermittent Oral Iron Supplementation vs. Daily Oral Iron Supplementation for the Treatment of Anemia in Pregnancy
Sponsor: The University of Texas Medical Branch, Galveston (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Unable to recruit enough participants
Enrollment: 14.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-27
Primary completion date: 2024-01-12
Completion date: 2024-01-12
Plan to share individual participant data: NO
Clinical trial NCT02720744: Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy
Official title: A Double-blind, Randomized, Placebo Controlled, Two Arm Multi-center Study to Assess the Efficacy and Safety of a Once Nightly Formulation of Sodium Oxybate for Extended-Release Oral Suspension (FT218) for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Subjects With Narcolepsy
Sponsor: Avadel (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 212.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-11-17
Primary completion date: 2020-03-25
Completion date: 2020-03-25
Clinical trial NCT04386811: Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD: a Proof-of-concept Tele-health Study of Stimulant-induced Improvement in Neurocognitive Functioning.
Official title: Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD: a Proof-of-concept Tele-health Study of Stimulant-induced Improvement in Neurocognitive Functioning.
Sponsor: Yale University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Following Yale University resuming in-person research activities, the investigators no longer had dedicated funding for the study and were unable to secure additional funding to meet the research goals.
Enrollment: 3.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-05
Primary completion date: 2020-09-29
Completion date: 2020-09-29
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03180684: Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)
Official title: A Phase 2, Randomized, Open Label, Efficacy Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™ 2000 Alone or in Combination With Imiquimod, for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Vulva
Sponsor: Inovio Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 33.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-08-31
Primary completion date: 2020-07-23
Completion date: 2020-12-18
Baseline population: mITT population included all participants who received at least 1 dose of VGX-3100 + EP (with or without imiquimod) and had an analysis endpoint of interest.
Plan to share individual participant data: NO
Clinical trial NCT04066790: Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
Official title: A Randomised, Multicenter, Open-label, Phase II Study Evaluating Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in Early Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2 - Positive Breast Cancer
Sponsor: Shanghai Jiao Tong University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: We terminated this trial and initiated a new one including pertuzumab.
Enrollment: 12.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-09-09
Primary completion date: 2020-04-30
Completion date: 2020-04-30
Plan to share individual participant data: NO
Clinical trial NCT04583956: ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19
Official title: A Multicenter Platform Trial of Putative Therapeutics for the Treatment of COVID-19 in Hospitalized Adults
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 214.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-23
Primary completion date: 2021-09-13
Completion date: 2021-09-13
Baseline population: The intention-to-treat (ITT) population includes all participants who were enrolled and randomized.
Clinical trial NCT03019796: Exercise Training Effects on Metabolic Syndrome: Interactions With Medication
Official title: Effects of Exercise Training as a Non-pharmacological Treatment for Metabolic Syndrome and Its Interactions With Subjects Habitual Medications.
Acronym: METSYND
Sponsor: University of Castilla-La Mancha (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: COMPLETED 
Enrollment: 40.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-07-31
Primary completion date: 2018-04-30
Completion date: 2020-08-31
Baseline population: The baseline trial is the non-medicated, no-exercise
Plan to share individual participant data: NO
Clinical trial NCT03087019: Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
Official title: A Phase II Trial of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
Sponsor: Dana-Farber Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 21.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-04-25
Primary completion date: 2020-08-04
Completion date: 2020-08-04
Plan to share individual participant data: NO
Clinical trial NCT04161495: A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A
Official title: A Phase 3 Open-Label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Patients ≥12 Years of Age With Severe Hemophilia A
Acronym: XTEND-1
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 159.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-11-19
Primary completion date: 2022-02-03
Completion date: 2022-02-03
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT03572478: Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer
Official title: A Phase Ib/IIa Study of Rucaparib (PARP Inhibitor) Combined With Nivolumab in Metastatic Castrate - Resistant Prostate Cancer and Advanced/Recurrent Endometrial Cancer
Sponsor: University of Chicago (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The study was terminated due to lack of efficacy.
Enrollment: 12.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-08-14
Primary completion date: 2020-02-29
Completion date: 2020-10-01
Clinical trial NCT03426631: DAW1033B2 in Obstructive Sleep Apnea
Official title: Effect of DAW1033B2 on Obstructive Sleep Apnea
Acronym: OsaStimB2
Sponsor: Brigham and Women's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 13.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-09-15
Primary completion date: 2019-10-01
Completion date: 2020-01-20
Plan to share individual participant data: NO
Clinical trial NCT04754230: Effect of Tranexamic Acid on Postoperative Bleeding Following Sinus and Nasal Surgery
Official title: Effect of Tranexamic Acid on Postoperative Bleeding Following Sinus and Nasal Surgery
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 40.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-06-17
Primary completion date: 2022-02-20
Completion date: 2022-02-20
Plan to share individual participant data: NO
IPD sharing description: No current plan to share data.
Clinical trial NCT04540393: AZD1222 Vaccine for the Prevention of COVID-19
Official title: A Phase III Open-label Study in Adults to Determine the Safety and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: The study was put on hold in September 2020 due to a safety concern in another trial but never restarted. In the meantime our clinical development program now includes a similar study with a different design, which we prefer to complete now.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-09-02
Primary completion date: 2020-12-04
Completion date: 2022-05-11
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Clinical trial NCT02671084: Sevoflurane and Percutaneous Coronary Intervention by Stent
Official title: Effect of Sevoflurane on CKMB Release After PCI With Drug-eluting Stents: a Randomised Trial
Sponsor: Instituto Dante Pazzanese de Cardiologia (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: interim analysis suggests futility
Enrollment: 701.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-02-29
Primary completion date: 2020-04-30
Completion date: 2020-04-30
Plan to share individual participant data: YES
IPD sharing description: Data will be published in journals
Clinical trial NCT02900560: Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer
Official title: Phase II Randomized Study of Pembrolizumab With or Without Epigenetic Modulation With CC-486 in Patients With Platinum-resistant Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Sponsor: Translational Research in Oncology (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Enrollment: 34.0 (ACTUAL)
Number of arms: 4.0
Start date: 2016-12-20
Primary completion date: 2021-05-27
Completion date: 2021-05-27
Limitations and caveats: Trial closed prematurely with 34 participant enrolled in Part A of the study. All of the treatment cohorts met at least one of the safety rejection criteria. Enrollment took 31 months, significantly longer than anticipated (24 months).
Plan to share individual participant data: NO
Clinical trial NCT03761537: Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7
Official title: A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre, Phase 3 Trial Investigating the Efficacy, Safety, and Tolerability of Tralokinumab Administered in Combination With Topical Corticosteroids to Adult Subjects With Severe Atopic Dermatitis
Acronym: ECZTRA 7
Sponsor: LEO Pharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 277.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-12-13
Primary completion date: 2020-04-21
Completion date: 2020-09-28
Plan to share individual participant data: YES
IPD access criteria: De-identified Individual Participant Data can be made available to researchers and is subject to approved scientifically sound research proposal and signed data-sharing agreement.
Clinical trial NCT04883528: Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019
Official title: Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019
Acronym: PARACOR-19
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 42.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-08-06
Primary completion date: 2023-06-13
Completion date: 2023-06-13
Plan to share individual participant data: NO
Clinical trial NCT01506609: Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer
Official title: A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 294.0 (ACTUAL)
Number of arms: 3.0
Start date: 2012-01-23
Primary completion date: 2018-12-13
Completion date: 2020-09-02
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Clinical trial NCT04023071: FT516 in Subjects With Advanced Hematologic Malignancies
Official title: A Phase I Study of FT516 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination With Monoclonal Antibodies in Relapsed/Refractory B-Cell Lymphoma
Sponsor: Fate Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The study was terminated by the Sponsor.
Enrollment: 72.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-10-04
Primary completion date: 2023-10-23
Completion date: 2023-10-23
Plan to share individual participant data: NO
Clinical trial NCT04119453: A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)
Official title: A Phase 2 Open-Label, Multicenter, Study to Evaluate the Efficacy and Safety of Rivoceranib in Subjects With Recurrent or Metastatic Adenoid Cystic Carcinoma of All Anatomic Sites of Origin
Sponsor: Elevar Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The RM-202 study was terminated by the Sponsor due to redirection of the rivoceranib development plan.
Enrollment: 80.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-01-22
Primary completion date: 2023-06-28
Completion date: 2023-06-28
Clinical trial NCT03883113: Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model
Official title: Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model
Sponsor: Barinthus Biotherapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 145.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-06-03
Primary completion date: 2019-12-16
Completion date: 2020-04-17
Clinical trial NCT04054752: Vaccine Response With NT-I7
Official title: A Phase 1/1b Study of Enhancement of Immune Reconstitution and Vaccine Responses With Administration of Recombinant Human IL-7-hyFc (NT-I7) in Older Subjects Following Chemotherapy
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: No subjects enrolled.
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2023-05-30
Primary completion date: 2023-11-01
Completion date: 2023-11-01
Plan to share individual participant data: YES
IPD sharing description: .All IPD recorded in the medical record will be shared with intramural investigators upon request. In addition, all large scale genomic sequencing data will be shared with subscribers to dbGAP.
IPD time frame: Clinical data available during the study and indefinitely. Genomic data are available once genomic data are uploaded per protocol GDS plan for as long as database is active.
IPD access criteria: Clinical data will be made available via subscription to BTRIS and with the permission of the study PI. Genomic data are made available via dbGaP through requests to the data custodians.
Clinical trial NCT04176016: Phase I Study of Radiolabeled OTSA101-DTPA in Patients With Relapsed or Refractory Synovial Sarcoma
Official title: Safety Study of Radiolabeled (111In or 90Y) OTSA101-DTPA, an Anti-Frizzled Homolog 10 (FZD10) Monoclonal Antibody, to Evaluate Safety and Pharmacokinetics in Patients With Relapsed or Refractory Synovial Sarcoma
Sponsor: OncoTherapy Science, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Some of the raw materials for the investigational drug are difficult to obtain and expensive.
Enrollment: 12.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-01-10
Primary completion date: 2024-01-11
Completion date: 2024-01-11
Plan to share individual participant data: NO
Clinical trial NCT04878484: Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors
Official title: A Phase 1 Open-label Study to Evaluate the Safety, Tolerability, and Activity of TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors
Sponsor: Athenex, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Poor recruitment
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-08-11
Primary completion date: 2022-10-31
Completion date: 2024-12-31
Plan to share individual participant data: NO
IPD sharing description: No patients enrolled therefore no data available to share.
Clinical trial NCT03554395: Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Gastric Cancer
Official title: Phase II Randomized Comparison Clinical Trial of Target Activated CIK for Advanced Gastric Cancer
Sponsor: Fuda Cancer Hospital, Guangzhou (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No participants enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-04-05
Primary completion date: 2020-05-20
Completion date: 2020-08-05